Healthcare provider profile · identity verified

Barbara L Starry, NP

Nurse Practitioner · AUBURN, IN · NPI 1306033683

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	355	50
Tramadol Hcl	Tramadol Hcl	304	50
Pregabalin	Pregabalin	210	15
Bumetanide	Bumetanide	204	27
Levothyroxine Sodium	Levothyroxine Sodium	174	25
Potassium Chloride	Potassium Chloride	154	24
Furosemide	Furosemide	128	24
Gemtesa	Vibegron	127	12
Pantoprazole Sodium	Pantoprazole Sodium	121	24
Carvedilol	Carvedilol	107	12
Ozempic	Semaglutide	100	14
Warfarin Sodium	Warfarin Sodium	93	11
Eliquis	Apixaban	92	15
Mirtazapine	Mirtazapine	90	19
Gabapentin	Gabapentin	85	16
Amlodipine Besylate	Amlodipine Besylate	80	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	78	14
Sucralfate	Sucralfate	77	suppressed
Metformin Hcl	Metformin Hcl	70	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	68	40
Lorazepam	Lorazepam	66	19
Meloxicam	Meloxicam	66	11
Omeprazole	Omeprazole	65	suppressed
Prednisone	Prednisone	62	46
Allopurinol	Allopurinol	61	11
Metoprolol Succinate	Metoprolol Succinate	61	suppressed
Fentanyl	Fentanyl	60	suppressed
Cephalexin	Cephalexin	59	44
Trulicity	Dulaglutide	59	13
Oxycodone Hcl	Oxycodone Hcl	57	suppressed
Atorvastatin Calcium	Atorvastatin Calcium	56	suppressed
Famotidine	Famotidine	55	11
Lisinopril	Lisinopril	53	suppressed
Baclofen	Baclofen	51	suppressed
Tradjenta	Linagliptin	51	suppressed
Losartan Potassium	Losartan Potassium	49	suppressed
Buprenorphine	Buprenorphine	48	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	45	suppressed
Farxiga	Dapagliflozin Propanediol	45	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	45	13
Hydralazine Hcl	Hydralazine Hcl	42	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	41	12
Hydrochlorothiazide	Hydrochlorothiazide	40	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	38	23
Clonidine Hcl	Clonidine Hcl	37	suppressed
Levetiracetam	Levetiracetam	37	suppressed
Midodrine Hcl	Midodrine Hcl	35	suppressed
Scopolamine	Scopolamine	35	suppressed
Torsemide	Torsemide	35	suppressed
Finasteride	Finasteride	34	suppressed
Nystatin	Nystatin	33	16
Spironolactone	Spironolactone	33	suppressed
Xarelto	Rivaroxaban	32	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	31	15
Duloxetine Hcl	Duloxetine Hcl	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	31	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	31	suppressed
Doxepin Hcl	Doxepin Hcl	30	suppressed
Humalog	Insulin Lispro	30	suppressed
Sertraline Hcl	Sertraline Hcl	30	suppressed
Ertapenem	Ertapenem Sodium	29	19
Levofloxacin	Levofloxacin	29	20
Lidocaine Hcl	Lidocaine Hcl	28	21
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	27	11
Ondansetron Hcl	Ondansetron Hcl	27	12
Carbidopa-Levodopa	Carbidopa/Levodopa	26	suppressed
Glipizide	Glipizide	26	suppressed
Loperamide	Loperamide Hcl	25	12
Arexvy	Rsvpref3 Antigen/As01e/Pf	23	23
Methocarbamol	Methocarbamol	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	21	suppressed
Latanoprost	Latanoprost	21	suppressed
Ondansetron Odt	Ondansetron	21	suppressed
Lacosamide	Lacosamide	20	suppressed
Alendronate Sodium	Alendronate Sodium	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Glycopyrrolate	Glycopyrrolate	19	suppressed
Humalog Kwikpen U-100	Insulin Lispro	19	suppressed
Modafinil	Modafinil	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	12
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	18	suppressed
Lidocaine Hcl	Lidocaine Hcl/Pf	18	16
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Dapagliflozin	Dapagliflozin Propanediol	17	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Ampicillin Trihydrate	Ampicillin Trihydrate	16	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	16	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	16	suppressed
Ibandronate Sodium	Ibandronate Sodium	16	suppressed
Linzess	Linaclotide	16	suppressed
Trazodone Hcl	Trazodone Hcl	16	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Fluticasone Propionate	Fluticasone Propionate	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Metolazone	Metolazone	14	suppressed
Azithromycin	Azithromycin	13	11
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Diazepam	Diazepam	13	suppressed
Enulose	Lactulose	13	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Morphine Sulfate	Morphine Sulfate	13	11
Nyamyc	Nystatin	13	suppressed
Trospium Chloride Er	Trospium Chloride	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Clonazepam	Clonazepam	12	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Ammonium Lactate	Ammonium Lactate	11	suppressed
Cilostazol	Cilostazol	11	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Permethrin	Permethrin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error